The scenario we outlined in our Q2 update has largely materialised, with Xspray reporting a Dasynoc CRL as the CDMO remains uncleared and th...
Xspray's Q2 report provided some color on the Dasynoc and Nilopki regulatory processes that anchor the case, with Dasynoc's PDUFA date now l...
Redeye updates on Xspray following a management call that provided some clarification on the Nilopki CRL.
Xspray received a CRL from the FDA for its Nilopki NDA ahead of the June 18 PDUFA date.
While the Q1 report was rather undramatic, Xspray stands before potentially transformative months ahead having two PDUFA dates during the su...
Xspray Pharma is close to achieving commercialisation, with two FDA decisions expected this summer.
Yesterday's rights issue announcement aligned closely to the scenario we discussed in our previous research update.
After a year marked by both progress and setbacks, Xspray enters a pivotal 2026, with two upcoming PDUFA decisions followed by the potential...
The public release of Xspray’s CRL on openFDA yesterday triggered a double-digit intraday decline in the stock, which ultimately closed down...
Redeye notes that it now appears beyond all reasonable doubt that Novartis will not initiate any litigation process against XS003, represent...
Redeye updates on Xspray following its Q3 report, which featured undramatic financials but offered additional insight into the ongoing regul...
Redeye leaves a short comment on Xspray following today's news that the FDA has accepted its NDA for XS003 with a PDUFA date set at June 18,...
Redeye updates its view on Xspray following last week’s CRL delaying the approval of Dasynoc.
Redeye provides its initial comments on Xspray following last night’s press release confirming a Complete Response Letter (CRL) for Dasynoc ...
Redeye provides an update on Xspray following its Q2 report.
Redeye comments on Xspray’s out-licensing of certain patents covering the commercialization of a dasatinib product in the US and, subsequent...
Redeye raises its base case following Xspray’s announcement that XS003 has achieved bioequivalence with Tasigna, paving the way for an NDA s...
Redeye comments on Xspray following yesterday evening’s announcement of a PDUFA date set for early October—consistent with the timeline alre...
Redeye comments on Xspray following an undramatic Q1 report.
Redeye provides an update on Xspray Pharma following its year-end report, which revealed no major surprises.
Redeye provides a comment on Xspray following yesterday's press release announcing a delay in the resubmission of its NDA to March/April 202...
Redeye updates its valuation model following Xspray's announcement of SEK235m in financing and the company's Q3 report, which reaffirmed the...
Redeye provides a brief comment on Xspray following yesterday's confirmation of the anticipated Q4 2024 NDA resubmission for Dasynoc.
Redeye updates its view on Xspray following the Dasynoc CRL and the Q2 report.
Redeye shares its initial comments on Xspray following the Dasynoc CRL.
Redeye leaves its comments on Xspray following a press release confirming that XS003 shows matching bioavailability to Tasigna at a more tha...
Redeye updates its view on Xspray Pharma following an undramatic Q1 2024 report.
Redeye comments on yesterday’s press release from Xspray that it has successfully scaled up its ASP formulation of its newly announced proje...
Redeye considers the declaration of intents for the TO6 warrants from Xspray's largest shareholders to be very supportive news, especially c...
Redeye updates its outlook for Xspray following its Q4 report, and we highlight that the recently announced PDUFA-date at the end of July ma...
Redeye returns with a slightly upwards adjusted valuation following the XS003 data and capital markets day.
Redeye views today's press release from Xspray positively.
Redeye has opened an Analyst Q&A in conjunction with the latest research update on Xspray Pharma.
Redeye makes minor changes to its fair value range following Xspray Pharma’s Q3 report, which contained no major surprises.
Redeye envisions an exciting period on the horizon for Xspray Pharma following the resolution of the Dasynoc patent litigation with BMS.
Redeye leaves a short comment on Xspray following today's exciting news that Xspray and Bristol Myers Squibb has reached a settlement in the...
Redeye updates on Xspray Pharma following its Q2 2023 report.
Redeye expresses disappointment following this morning's news that Xspray has received a CRL for its NDA.
Redeye leaves its comments on Xspray following the investor day held last week, which shed light on the current operations and pipeline.
Redeye comments on Xspray Pharma following its Q1 2023 report.
Redeye comments its key takeaways from Xspray’s Q1 2023 report released this morning.
Today Xspray announced a SEK300m rights issue. The capital injection came as no surprise and was partly already included in our valuation, b...
Redeye comments on Xspray following today’s news that the court has decided to deny the “motion to dismiss” in the XS004 lawsuit.
Redeye ups its fair value range for Xspray in anticipation of a transformative year ahead.
Redeye leaves comments on Xspray following its Q4 2022 report, which left updates on the commercialization strategy of XS004 and also announ...
Redeye leaves its comments on Xspray Pharma’s Q3 2022 report.
Redeye positively views yesterday evening’s news that Xspray, through a directed share issue, has secured SEK 100m in funding, targeting its...
Today, legal documents from the BMS vs. Xspray litigation process were released, in which Xspray notifies the court that it requests a pre-m...
Redeye leaves its view on Xspray following friday's Q2 report, where it announced a vision of generating an excess of USD 250m in annual rev...
Redeye leaves its view on Xspray following today’s Q1 report.
Redeye leaves its comment on Xspray following the announcement of today’s year-end report.
Redeye leaves its view on Xspray's Q2 report and expects the second half of 2021 to be eventful for the company.
Redeye leaves a comment on Xspray following the announcement that its HyNap-Dasa 505(b)(2) reached bioequivalence compared to its reference ...
